Remote Nutrition Support Program Comparing STRONG Intervention and Usual Care for Adults with Gastroesophageal Cancer
Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-04-01
80
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the STRONG intervention compares with usual care in reducing malnutrition among patients with gastroesophageal cancer. This study focuses on individuals with locally advanced or metastatic gastroesophageal cancer who are planning to begin chemotherapy, radiation therapy, or surgery. The goal is to improve nutritional status and quality of life in this patient group through remote observation and nutrition guidance.
Participants in the STRONG intervention group will have an initial consultation and biweekly follow-up visits with a dietitian for 90 days. These visits include reviewing dietary plans, food logs tracked daily using a Fitbit app and wearable device, and discussing challenges to improve intake. The usual care group will be referred to a dietitian based on their clinicians discretion. Both groups will complete six questionnaires and may opt into voluntary interviews about the intervention.
Throughout the study, participants will complete surveys assessing nutrition impact symptoms, quality of life, and treatment adherence at baseline, 3 months, and 6 months. Researchers will monitor recruitment, retention, adherence to visits, and satisfaction with the MyPlate app over up to six months, with longer tracking of progression-free survival up to 48 months. Data collection includes Fitbit food logs, dietitian telehealth visits, and social determinants of health surveys. The total participation time varies, with follow-ups extending to six months post-intervention.
CONDITIONS
Brief Title
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
Research Team
E
Emma Hume
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
H. Lee Moffitt Cancer Center and Research Institute
Lead Sponsor
United States Department of Defense
Collaborating Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
STRONG Intervention
Usual Care Intervention
What it is
A structured remote nutrition support program combining dietitian consultations via telehealth, food‑logging support via Fitbit, symptom and nutrition surveys
A physician‑discretion referral to a dietitian without structured telehealth or digital tracking support
Role in trial
Tested intervention arm providing proactive supportive care
Control arm representing standard referral practice
Primary use
Supportive nutrition guidance during chemotherapy and radiotherapy planning and follow‑up
Usual dietitian referral based on clinical discretion during treatment
How it is given or performed
Dietitian telehealth visits (bi‑weekly baseline, monthly for 90 days, and at 4‑ and 6‑month follow‑up) plus surveys and Fitbit‑based food logging
Referral to dietitian made at provider’s discretion; content and frequency not structured
Evidence status
Effectiveness under evaluation for feasibility, adherence, patient‑reported outcomes
Effectiveness not structured or evaluated beyond standard supportive referral
Important risks
Potential digital access barriers and technology dependence; no explicit safety concerns outlined
No additional risks beyond routine clinical referral
Important limitations
Requires reliable internet access, digital literacy, and regular device use; feasibility in low‑resource settings uncertain
Variability in referral timing and content may lead to inconsistent nutrition support
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Participants must be 18 years of age or older
Participants must have locally advanced or metastatic gastroesophageal cancer
Participants must plan to initiate chemotherapy and/or radiation therapy with a plan to have surgery or definitive treatment follow up at Moffitt
Participants must be able to speak and read Spanish and/or English
Participants must be able to provide informed consent
You will not qualify if you...
Participants have a documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g. severe dementia)
Use of feeding tubes at the time of study enrollment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or virtual) for eligibility assessment
Treatment
Duration - Up to 90 days
Participants receive nutrition guidance through individualized dietitian consultations and complete surveys and food logging using Fitbit devices. The intervention includes biweekly dietitian telehealth visits during a 90-day period, with dietary plans reviewed and challenges discussed.
Biweekly telehealth visits during the 90-day intervention period
Follow-up
Duration - Up to 3 months post-intervention
Participants continue to complete surveys and dietitian telehealth visits at 4 and 6 months post-intervention to assess nutritional status and quality of life.
2 telehealth visits at 4 and 6 months post-intervention
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Phase IIIa Study Evaluating DA-3501 for Advanced Gastric, Gastro-Esophageal Junction, and Pancreatic Ductal Adenocarcinomas
Assessing Safety, Effectiveness, and Proper Dose Given Every Three Weeks
Open-label Phase 2 Study Evaluating Zanidatamab for Previously Treated HER2-expressing Solid Tumors
Phase 1 Open Label Study of MGC030 for Advanced Solid Tumors Including Dose Escalation, Optimization, and Expansion
Phase 2 Trial Comparing Standard and Extended Dosing Intervals of Nivolumab, Pembrolizumab, and Atezolizumab in Advanced Gastric, Liver, and Lung Cancers
Adjuvant Chemotherapy and Immunotherapy After Surgery for Esophageal and Esophageal-Gastric Junction Cancer With High Risk of Recurrence
Phase 12a Study Evaluating MDX2001 Monotherapy for Advanced Solid Tumors
A Multicenter, Open-label Clinical Trial Assessing Safety and Anti-tumor Activity
Study of Immune Changes in Tumor Environment During Standard Chemotherapy for Localized and Resectable Gastric and Gastroesophageal Junction Cancers
Phase 2 Study Comparing Pulsed Low-Dose-Rate Radiation Chemoradiation Versus Standard Chemoradiation for Treating Locally Advanced Esophageal Cancer
Study Collecting Blood and Tissue Samples to Evaluate Nateras Molecular Residual Disease Tests in Various Solid Tumors
Remote Nutrition Support Program Comparing STRONG Intervention and Usual Care for Adults with Gastroesophageal Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A patient-mediated implementation strategy to improve nutrition care delivery for esophageal and gastric cancer: a study protocol for a pilot randomized controlled trial.